All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?
How do you incorporate MRD into treatment decision-making in clinical practice?
Van Besien begins by discussing the complexities around the two major technologies we use to detect MRD, flow cytometry and molecular testing. He outlines reliable MRD tests, settings in which they can be used, and treatment options, such as MRD testing during induction for MPN1 mutated AML. He also describes the necessity for allogenic transplant consolidation in MRD- patients. Finally, he highlights the increasing data on maintenance therapy for patients that remain MRD+ e.g. TKI inhibitors.
Your opinion matters
Decitabine-containing conditioning regimens for allo-HSCT may reduce rates of Grade II–IV aGvHD
Decitabine is a pyrimidine analogue that inhibits cytosine methylation, resulting in activation of silent genes and thus has an anti-leukemic effect.
Prognostic impact of FLT3-ITD and CEBPA mutations in cytogenetically normal AML
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) have varied clinical outcomes, and advances in molecular analysis in recent years have highlighted...
Subscribe to get the best content related to AML delivered to your inbox